


UPDATE ON CALCITONIN GENE-RELATED PEPTIDE MONOCLONAL ANTIBODIES



The HSE introduced a managed access protocol (MAP) for calcitonin gene-related peptide (CGRP) monoclonal antibodies (MABs) in September 2021. The aim of the MAP is to provide patients with chronic migraine who have failed three or more prophylactic treatments, with access to CGRP MABs. These are biological medicines used to prevent migraine, and include erenumab, fremanezumab and galcanezumab under the High Tech Arrangement.

To date, the HSE have approved 60 consultants to apply for reimbursement for CGRP MABs under this protocol. By December 2024, 1,765 patients were accessing treatment with a CGRP MAB under the High Tech Arrangement.

April 2025

HSE-Medicines Management Programme.